Close Menu
Daily Guardian
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
What's On

B.C. Conservative leader ‘ready to rock’

September 26, 2026

Apple hit with $5.7 billion in damages over haptic patents

September 26, 2026

4 killed after helicopter crashes in field near Montreal

September 26, 2026

Lawyer wins case against multinational firm behind day school settlement

September 26, 2026

OpenAI pauses training of its ‘most capable models’

September 26, 2026
Facebook X (Twitter) Instagram
Finance Pro
Facebook X (Twitter) Instagram
Daily Guardian
Subscribe
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
Daily Guardian
Home » United States Generic Drugs Market Research Report 2023-2028 – Rise In the Number of Generic Drug Approvals
Press Release

United States Generic Drugs Market Research Report 2023-2028 – Rise In the Number of Generic Drug Approvals

By News RoomDecember 12, 20234 Mins Read
United States Generic Drugs Market Research Report 2023-2028 – Rise In the Number of Generic Drug Approvals
Share
Facebook Twitter LinkedIn Pinterest Email

Dublin, Dec. 12, 2023 (GLOBE NEWSWIRE) — The “United States Generic Drugs Market, Competition, Forecast and Opportunities, 2018-2028” report has been added to ResearchAndMarkets.com’s offering.

United States Generic Drugs Market has valued at USD 104.23 Billion in 2022 and is anticipated to project steady growth in the forecast period with a CAGR of 7.46% through 2028.

The availability of generic drugs brings several advantages to the healthcare industry. One of the major benefits is the lower cost associated with generic options, which provides increased accessibility and affordability to a wider population. This, in turn, makes healthcare more affordable and accessible to individuals who may otherwise struggle to afford expensive brand-name drugs.

Additionally, generic drugs play a crucial role in promoting competition in the pharmaceutical market, thus driving innovation and enhancing the overall efficiency of healthcare systems in the United States. With their ability to offer cost-effective alternatives to brand-name drugs, generic drugs have become an integral part of the healthcare landscape. By expanding options and providing affordable alternatives, they contribute significantly to improving patient outcomes and ensuring the provision of high-quality healthcare for all.

Key Attributes:

Report Attribute Details
No. of Pages 80
Forecast Period 2022 – 2028
Estimated Market Value (USD) in 2022 $104.23 Billion
Forecasted Market Value (USD) by 2028 $160.19 Billion
Compound Annual Growth Rate 7.4%
Regions Covered United States

Key Market Drivers

  • Growing Demand for Chronic Disease Management: The rising prevalence of chronic diseases, coupled with the aging population, is driving the demand for cost-effective medication options. Generic drugs offer affordable alternatives for managing chronic diseases, making them appealing to patients, healthcare providers, and payers.
  • Increasing Drug Shortage Across the Region: Drug shortages of brand-name drugs can lead to increased utilization of generic alternatives. Healthcare providers and pharmacies may turn to generic drugs during shortages, ensuring uninterrupted patient care and promoting their utilization.
  • Presence of Patent Cliffs: Patent expirations for brand-name drugs create opportunities for generic manufacturers to produce more cost-effective alternatives. This competition promotes price transparency and drives down medication costs, benefiting patients and healthcare systems.
  • Easy Availability and Affordability: Generic drugs are readily available, cost-effective, and meet rigorous FDA standards for safety and efficacy. Insurance incentives, government initiatives, and the rising cost of healthcare contribute to their demand.

Key Market Challenges:

  • Stringent Government Regulations: Stringent regulatory requirements, including bioequivalence studies, patent litigation, and the “pay-for-delay” deals, can discourage pharmaceutical firms from producing generic drugs, limiting their availability and affordability.
  • Adverse Effects Associated with the Drugs: Concerns about potential side effects and inconsistent efficacy of generic drugs may lead to a more cautious approach by consumers and healthcare providers, decreasing their demand.

Key Market Trends:

  • Rising Cost of Healthcare: The increasing cost of healthcare in the United States is driving the demand for more affordable medication options. Generic drugs provide cost-effective alternatives without compromising on quality or therapeutic benefits.
  • Rise In the Number of Generic Drug Approvals: The FDA’s commitment to promoting generic drug competition has led to a surge in approvals. This trend facilitates the entry of cost-effective therapeutic alternatives into the market, meeting the demands of patients and healthcare providers.

Segmental Insights:

  • Type: Small Molecule Generics are expected to dominate the market, offering reliable and affordable options for patients. While biosimilars also offer cost-saving potential, their market share may grow more slowly due to regulatory complexities.
  • Mode of Drug Delivery: The Oral segment is expected to maintain dominance, offering convenience, precise dosing, lower manufacturing costs, and customizability, making it the preferred choice for both patients and healthcare professionals.

Regional Insights:

  • The Midwest region is projected to maintain its dominance in the United States generic drugs market due to a high prevalence of chronic diseases, a large aging population, the presence of major pharmaceutical companies, a robust healthcare infrastructure, and government initiatives promoting generic drug usage.

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the United States Generic Drugs Market.

  • Teva Pharmaceuticals USA, Inc.
  • Pfizer Inc.
  • Sandoz US
  • Endo International plc
  • Aurobindo Pharma USA, Inc.
  • Abbott Laboratories Inc.
  • Eli Lilly and Company
  • Sun Pharma USA
  • Lupin Pharmaceuticals, Inc.
  • Zydus Pharmaceuticals USA

Report Scope:

United States Generic Drugs Market, By Type:

  • Small Molecule Generics
  • Biosimilars

United States Generic Drugs Market, By Application:

  • Cardiovascular Diseases
  • Diabetes
  • Neurology
  • Oncology
  • Infectious Diseases
  • Other

United States Generic Drugs Market, By Mode of Drug Delivery:

  • Oral
  • Topical
  • Parenteral
  • Others

United States Generic Drugs Market, By Form:

  • Tablet
  • Capsule
  • Injection
  • Others

United States Generic Drugs Market, By Source:

  • In House
  • Contract Manufacturing Organizations

United States Generic Drugs Market, By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

United States Generic Drugs Market, By Region:

  • Northeast Region
  • Midwest Region
  • West Region
  • South Region

For more information about this report visit https://www.researchandmarkets.com/r/78s18x

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

  • U.S. Generic Drugs Market

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Keep Reading

BABA 9-DAY DEADLINE ALERT: Alibaba Group Holding Limited Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before October 5, 2026 Lead Plaintiff Deadline

PNR 6-DAY DEADLINE ALERT: Pentair plc Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before October 2, 2026 Lead Plaintiff Deadline

Upcoming Blaze Wilde Podcast on Snapchat Exploring Pop Culture, Politics, and Life Between Arab and American Culture

Yan’an Apple Price Index Debuts in Shanghai: Unlocking Fair, Quality-Based Fruit Pricing

WSE INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Wise Group plc (WSE) Investors of Securities Class Action Lawsuit Deadline on September 29, 2026

Sixthfin Financial Close Management Software Supports UK Internal Control Evidence for Provision 29 and ECCTA Failure-to-Prevent-Fraud Across 38 ERP Systems in 2026

RXT INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Rackspace Technology Investors of Securities Class Action Lawsuit Deadline on September 28, 2026

PNR INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Pentair (PNR) Investors of Securities Class Action Lawsuit Deadline on October 2, 2026

CAPR INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Capricor Investors of Securities Class Action Lawsuit Deadline on September 28, 2026

Editors Picks

Apple hit with $5.7 billion in damages over haptic patents

September 26, 2026

4 killed after helicopter crashes in field near Montreal

September 26, 2026

Lawyer wins case against multinational firm behind day school settlement

September 26, 2026

OpenAI pauses training of its ‘most capable models’

September 26, 2026

Latest News

Kids turned the comment section of an NPR podcast into a group chat

September 26, 2026

BABA 9-DAY DEADLINE ALERT: Alibaba Group Holding Limited Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before October 5, 2026 Lead Plaintiff Deadline

September 26, 2026

PNR 6-DAY DEADLINE ALERT: Pentair plc Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before October 2, 2026 Lead Plaintiff Deadline

September 26, 2026
Facebook X (Twitter) Pinterest TikTok Instagram
© 2026 Daily Guardian Canada. All Rights Reserved.
  • Privacy Policy
  • Terms
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.

Go to mobile version